Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Nci Sbir Fy2025 Solicitation topic
No spam. Unsubscribe anytime.
NCI SBIR details FY2025 contract topics: diagnostics, digital biomarkers, digital twins, wearables and biomaterials
Summary
The National Cancer Institute’s SBIR Development Center outlined FY2025 contract topics including a point‑of‑care HPV antibody test, cancer‑specific digital biomarkers and endpoints, digital twin tools for radiation therapy, wearables for post‑treatment monitoring, and advanced biomaterials for cancer modeling; applicants were told to consult the solicitation and contact the Office of Acquisitions.
The National Cancer Institute’s Small Business Innovation Research (NCI SBIR) Development Center on its Innovation Lab podcast laid out the FY2025 contract solicitation topics and application guidance for companies seeking to translate cancer technologies to market.
Dr. Melissa Lee, an NCI SBIR program director, described five remaining contract topics for FY2025. She said one topic seeks "a rapid point of care test to screen high risk individuals for HPV‑related oropharyngeal cancers" by detecting antibodies to HPV types 16 and 18 E6 and E7 proteins. "The goal of this topic is to develop a rapid point of care test to screen high risk individuals," she said.
Another topic invites development of digital biomarkers and endpoints produced from physiological and behavioral data to support cancer care. Dr. Lee said such tools could identify early adverse events or measure treatment tolerance, giving the clinical team an opportunity to intervene sooner; she cited heart monitoring as an example in patients receiving cardiotoxic chemotherapies.
A separate topic targets digital twin software for radiation therapy—virtual, multidimensional patient models intended to allow virtual testing and prediction to help clinical decision‑making before, during, or after radiation treatment.
On medical devices, the solicitation calls for wearable technologies that pair sensors and analytical software to remotely monitor cancer patients after treatment. Dr. Lee said the agency is looking for combined hardware and software products that support post‑treatment surveillance.
In research tools, NCI SBIR included a topic on advanced biomaterials designed to improve cancer modeling by addressing reproducibility, mechanical properties, and biocompatibility to support more rigorous research and drug screening.
On next steps, Dr. Lee urged applicants to "read the solicitation carefully," noting the document contains page limits, required deliverables and explicit instructions about who to contact. She emphasized that this opportunity is a contract, not a grant, and said inquiries regarding procurement should be directed to the Office of Acquisitions; the solicitation will list the office’s email address and other contact information. The hosts also pointed listeners to upcoming webinars, the program’s LinkedIn page and mailing list, and the SBIR website, sbir.cancer.gov, for updates.
The episode closed with a sign‑off from host Monique Pond and reminders to consult the FY2025 solicitation for full instructions and contact details.
